|
|
Radiation protection assessment for 177Lu-Dotatate therapy |
GENG Jianhua1, ZHANG Jinming2, WANG Xiaotao3, CHEN Yingmao2 |
1. Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021 China; 2. Department of Nuclear Medicine, First Medical Center of Chinese PLA General Hospital, Beijing 100853 China; 3. Nuclear and Radiation Safety Center, Beijing 102442 China |
|
|
Abstract Objective To comprehensively evaluate the radiation protection of 177Lu-Dotatate therapy, and to provide a reference for standardizing and restraining patient behavior and activities after discharge and establishing relevant standards. Methods The radiation protection of 177Lu-Dotatate therapy started with the infusion of radiopharmaceuticals. The time points of each event in daily activities during and after therapy were listed in a chronological order, as well asthe persons with possible radiation exposure and their contact distance and contact duration in each event. The in vivo pharmacokinetic data in the instructions of 177Lu-Dotatate were used to estimate 177Lu activity in the patient’s body at each time point, and the formula for radiation dose in GBZ 120—2020 was used to estimate the radiation dose of the patient on the persons around him/her. Results 177Lu-Dotatate was administered to the patient at a dose of 7400 MBq when the patient attended the outpatient service or was hospitalized for treatment. The cumulative radiation dose was calculated for the medical staff, the public, colleagues, caregivers, adult family members, and the family members of children aged 3~10 years, and the measures for standardizing and restraining the patient’s behaviors were given when the dose constraint value for related persons in national standard was met. The conditions for realizing the requirement in national standard that pregnant women and family members aged < 3 years should avoid contact was also proposed in this article. Conclusion From the perspective of radiation protection, under the premise of standardizing and restraining the behavior of patients treated with177Lu-Dotatate after discharge, both ambulatory treatment and hospitalization are safe and feasible; if the activities of patients are no restrained after discharge, the radiation dose for family members, the public, and colleagues might exceed the dose limits or constraint values in relevant national standards.
|
Received: 13 June 2021
|
|
|
|
|
[1] 马秀凤, 张君丽, 李洪玉, 等. 177Lu标记利妥昔单抗的实验研究[J]. 中国辐射卫生,2016,25(2):157-160. DOI: 10.13491/j.cnki.issn.1004-714X.2016.02.009 Ma XF, Zhang JL, Li HY, et al. Preliminary preparation of 177Lu-labeled rituximab[J]. Chin J Radiol Health, 2016, 25(2): 157-160. DOI: 10.13491/j.cnki.issn.1004-714X.2016.02.009 [2] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5): 800-816. DOI: 10.1007/s00259-012-2330-6 [3] International Atomic Energy Agency. Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours[M]. Vienna: International Atomic Energy Agency, 2013: 97-123.https://www.iaea.org [4] Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE[J]. J Nucl Med, 2019, 60(7): 937-943. DOI: 10.2967/jnumed.118.230607 [5] Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844-860. DOI: 10.1016/j.annonc.2020.03.304 [6] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors[J]. N Engl J Med, 2017, 376(2): 125-135. DOI: 10.1056/NEJMoa1607427 [7] Nicolini S, Bodei L, Bongiovanni A, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2021, 48(10): 3260-3267. DOI: 10.1007/s00259-021-05236-z [8] Levart D, Kalogianni E, Corcoran B, et al. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours[J]. EJNMMI Phys, 2019, 6(1): 7. DOI: 10.1186/s40658-019-0243-1 [9] Kendi AT, Halfdanarson TR, Packard A, et al. Therapy with 177Lu-DOTATATE: Clinical implementation and impact on care of patients with neuroendocrine tumors[J]. AJR Am J Roentgenol, 2019, 213(2): 309-317. DOI: 10.2214/AJR.19.21123 [10] Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors[J]. Ann Nucl Med, 2014, 28(6): 531-539. DOI: 10.1007/s12149-014-0843-8 [11] Olmstead C, Cruz K, Stodilka R, etal. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol[J]. Nucl Med Commun, 2015, 36(2): 129-134. DOI: 10.1097/MNM.0000000000000232 [12] Basu S, Chakraborty S, Parghane RV, et al. One decade of ‘Bench-to-Bedside’ peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through ‘Direct’ neutron activation route: lessons learnt including practice evolution in an Indian setting[J]. Am J Nucl Med Mol Imaging, 2020, 10(4): 178-211 [13] Lawal I, Louw L, Warwick J, et al. The college of nuclear physicians of south Africa practice guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours[J]. S Afr N J Surg, 2018, 56(3): 55-64 [14] Lim LE, Chan DL, Thomas D, et al. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours[J]. Oncotarget, 2020, 11(27): 2636-2646. DOI: 10.18632/oncotarget.27659 [15] Hosono M, Ikebuchi H, Nakamura Y, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd Ed. )[J]. Ann Nucl Med, 2018, 32(3): 217-235. DOI: 10.1007/s12149-018-1230-7 [16] Sandström M, Garske-Román U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment[J]. J Nucl Med, 2013, 54(1): 33-41. DOI: 10.2967/jnumed.112.107524 [17] 中华人民共和国国家卫生健康委员会. GBZ 120—2020 核医学放射防护要求[S]. 北京: 中国标准出版社, 2021. GBZ 120—2020 State Health Commission of the people's Republic of China. Requirements for radiological protection in nuclear medicine[S]. Beijing: Standards Press of China, 2021. [18] 潘自强. 辐射安全手册[M]. 北京: 科学出版社, 2011. Pan ZQ. Radiation safety manual [M]. Beijing: Science Press, 2011. [19] 张永刚. 医学辐射防护学[M]. 北京: 高等教育出版社, 2011: 169. Zhang YG. Medical radiation protection [M]. Beijing: Higher Education Press, 2011: 169. [20] 中华人民共和国国家质量监督检验检疫总局. GB 18871—2002 电离辐射防护与辐射源安全基本标准[S]. 北京: 中国标准出版社, 2003. General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China. GB 18871—2002 Basic standards for protection against ionizing radiation and for the safety of radiation sources[S]. Beijing: Standards Press of China, 2003. [21] International Atomic Energy Agency. IAEA Safety Reports Series No. 63 Release of Patients After Radionuclide Tgerapy[S].Vienna: International Atomic Energy Agency, 2009: 14. https://www.iaea.org
|
|
|
|